Pure Global
NCT01957995

Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors

An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors
University of Southern California·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
nanosomal docetaxel lipid suspension
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Southern California
Location
Los Angeles, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Nov 08, 2013
End date
Jul 14, 2016
Enrollment
13 participants
Primary outcome

Pharmacokinetic profile of nanosomal docetaxel lipid suspension

Summary

This randomized phase I trial studies the side effects and best dose of nanosomal docetaxel
 lipid suspension in treating patients with advanced solid tumors. Drugs used in chemotherapy,
 such as nanosomal docetaxel lipid suspension, work in different ways to stop the growth of
 tumor cells, either by killing the cells or by stopping them from dividing.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01957995
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01957995 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Southern California and is currently Completed. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 13 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.